Stenabolic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-11. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
==== Immunohistochemistry Approaches ==== As an antibody technique, immunohistochemistry (IHC) allows for validating protein presence. It, and immunocytochemistry, allow for surveying the localization of proteases on a tissue or cellular scale respectively. It also can evaluate for the localization of cleavage products using monoclonal antibodies raised against neo-epitopes of cleavage sites produced by protease processing. Unfortunately, in addition to providing little functional information, IHC is also non-quantitative, making it an unappealing option for describing degradomics on system-wide scales.
== Adverse effects == Increased urination is a commonly reported side effect, particularly during the initial phase following treatment initiation; this is mostly transient and tends to reduce with sustained treatment. Common side effects for antimineralocorticoid medications include nausea and vomiting, stomach cramps and diarrhoea. Clinically significant hyperkalemia is possible, and warrants serum potassium monitoring on a periodic basis. The pathophysiology of hyperkalemia is that antimineralocorticoid medications reduce potassium (K) excretion.
10 December: The Taranaki Regional Council confirms that Lake Rotomanu in New Plymouth will be drained over the next four days commencing 11 December in response to a Corbicula fluminea infestation. The Court of Appeal of New Zealand overturns a 2023 High Court ruling finding that toy company Zuru's packaging had infringed on Lego's trademark. The New Zealand Government launches a new mobile app called "Govt.nz" to make it easier for people to access government services. 11 December: The New Zealand Parliament passes two urgent laws delaying a ban on farrowing crates by ten years and legislation amending the Fast-track Approvals Act 2024. Parliament rejects a 36,549-strong petition organised by Queenstown Volunteer Fire Brigade secretary Katherine Lamont for volunteer firefighters to receive the same ACC coverage as professional firefighters. Principals affiliated with the New Zealand Educational Institute reject a 4.6 percent government pay offer, citing the exclusion of a curriculum change allowance. 12 December: The Christchurch District Court fines three companies Skyline Enterprises, Naylor Love Central Otago Limited and Wilsons Contractors Limited over a total of NZ$500,000 for their role in a landslide that damaged a Queenstown street during the 2023 southern New Zealand floods. The three companies also pleaded guilty to breaching the Resource Management Act 1991. Former Gloriavale Christian Community leader Howard Temple is sentenced to 26 months in jail for indecently assaulting girls and women over a 20 year period.
Sources: en.wikipedia.org
== Regulation == Noradrenaline has been shown to increase endorphin production within inflamed tissues, resulting in an analgesic effect; the stimulation of sympathetic nerves by electro-acupuncture is believed to be the cause of its analgesic effects.
== Fibronectin genetic variation as a protective factor against Alzheimer's disease == A specific genetic variation in Fibronectin gene was shown to reduce the risk of developing Alzheimer's disease in a multicenter, multiethnic genetic epidemiology and functional genomics study. This effect is believed to be through enhancing the brain's ability to clear the toxic waste and protein accumulation through the blood–brain barrier. A follow-up mechanistic study showed that astrocyte-derived fibronectin accumulates at the gliovascular interface in the presence of the APOE ε4 allele, disrupting VEGFA/HB-EGF/IGF-1 growth factor signaling and causing blood–brain barrier leakage, thereby establishing fibronectin as a mediator of APOE4-driven vascular dysfunction in Alzheimer's disease.
=== Europe === Following discussions on the safety of certain pharmaceutical products derived from kava and sold in Germany, the EU imposed a temporary ban on imports of kava-based pharmaceutical products in 2002. The sale of kava plant became regulated in Switzerland, France, and in prepared form in the Netherlands. Some Pacific island states, which had been benefiting from the export of kava to the pharmaceutical companies, have attempted to overturn the EU ban on kava-based pharmaceutical products by invoking international trade agreements: Fiji, Samoa, Tonga, and Vanuatu argued at the WTO that the ban was imposed with insufficient evidence. The pressure prompted Germany to reconsider the evidence base for banning kava-based pharmaceutical products. On 10 June 2014, the German Administrative Court overturned the 2002 ban, making selling kava as a medicine legal, albeit strictly regulated; personal possession of kava has never been illegal. In Germany, kava-based pharmaceutical preparations are currently prescription drugs. Furthermore, patient and professional information brochures have been redesigned to warn about potential side effects. These strict measures have been opposed by some of the leading kava scientists. In early 2016, a court case was filed against the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM/German Federal Institute for Drugs and Medical Devices), arguing that the new regulatory regime is too strict and not justified.
=== Soluble (sRAGE) === The soluble form of RAGE (sRAGE) only includes the extracellular domain and lacks both the transmembrane and cytoplasmic domains. sRAGE can be generated through two primary mechanisms:
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.